ExoFlo™
Phase 2- Indications
- COVID-19 with moderate-to-severe ARDS, Perianal fistulizing Crohn's disease
Company intelligence / Profile preview
Direct investors
Austin, Texas, United Statesdirectbiologics.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 2
01
Overview
Direct Biologics is a late-stage clinical biotechnology company focused on developing regenerative medical products derived from bone marrow-derived mesenchymal stem cells (MSCs). The company's lead product candidate, ExoFlo, is an investigational extracellular vesicle (EV) product that leverages the anti-inflammatory and regenerative properties of exosomes to treat severe inflammatory conditions. Direct Biologics is currently conducting a Phase 3 clinical trial for ExoFlo in the treatment of Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19. Beyond respiratory distress, the company is exploring applications in inflammatory bowel disease and musculoskeletal conditions.
- Therapeutic areas
- RheumatologyGastroenterologyPulmonologyInfectious Diseases
- Modalities
- Exosome-based therapyExtracellular vesiclesBiologic
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Direct investors.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Direct investors.